Aromatase inhibitors in the management of early breast cancer: The TEAM trial

European Journal of Surgical Oncology

Volumn 35, Issue 3, 2009, Pages 333-

  Markopoulos, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EXEMESTANE; HORMONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; LETTER; LONG TERM CARE; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION;

AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 59649098987     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.03.016     Document Type: Letter

References (5)

1. Nabholtz J.M. Aromatase inhibitors in the management of early breast cancer. Eur J Surg Oncol 34 11 (2008) 1199-1207
2. Markopoulos C., Polychronis A., Zobolas V., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93 1 (2005) 61-66
3. Jones S., Cantrell J., Vukelja S., et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a tamoxifen exemestane adjuvant multicenter trial substudy. J Clin Oncol 25 30 (2007) 4765-4771
4. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 350 (2004) 1081-1092
5. Thürlimann B., Keshaviah A., Coates A.S., et al., Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757